Close Menu

Biocept

The San Diego-based company said that the number of commercial samples received during the quarter grew 66 percent year over year.

The tubes and collection kits meet the requirements of the European In-Vitro Diagnostic Devices Directive, and the company can now commercialize the devices throughout Europe.

The company said it will use the net proceeds for general corporate purposes and to fund ongoing operations and expansion of its business.

The validation of its current CLIA testing comes as Biocept is in the early stages of expanding to provide kit versions of its liquid biopsy tests.

The firm has a 180-day grace period in which to regain compliance, by maintaining a $1.00 minimum closing bid price for at least 10 consecutive business days.

Buoyed by a 26 percent increase in test volume, the firm's revenues were $1.2 million for the quarter, compared to $822,000 last year.

Get the latest news from Biocept, Caris Life Sciences, PerkinElmer, Inform Diagnostics, CompuNet Clinical Labs, and Drawbridge Health for the week of 7/26/19.

The company said adopters are ordering tests in areas of great interest, like CTC and blood biomarker monitoring, despite a lack of reimbursement.

Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.

The company saw $1.0 million in revenues for the quarter, including $976,000 from commercial testing, and attributed the growth to its pathology partnership initiative.

Pages